One-Pot Cysteine-Engineered Antibody Conjugation Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The process of preparing antibody-drug conjugates (ADCs) with cysteine-engineered antibodies is complex and inefficient due to the need for multiple purification steps and reduction/oxidation processes, making large-scale manufacturing cumbersome.
Innovation Solution
A one-pot process that reacts a reducing agent with a capped cell-binding agent to form a reduced form with a free thiol group, which is then oxidized selectively without purifying the intermediate, allowing direct conjugation with a cytotoxic agent without intermediate purification steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple purification steps and reduction/oxidation processes are used to prepare ADCs with cysteine-engineered antibodies, then the purity of the final product is improved, but the process complexity and manufacturing time increase significantly
Solution Approach 1:
The patent combines multiple sequential steps (reduction, capping agent removal, oxidation, and conjugation) into a single integrated one-pot process. The reducing agent, capping agent, oxidizing agent, and cytotoxic agent are all added to the same reaction vessel in sequence, eliminating the need for intermediate purification steps and significantly simplifying the manufacturing process while maintaining ADC purity
Solution Approach 2:
The patent implements a continuous one-pot process where the reduction, de-capping, oxidation, and conjugation reactions proceed sequentially without interruption or purification steps in between. This continuous action maintains the reactive thiol groups available for conjugation throughout the process, improving both efficiency and purity while reducing process complexity
2Manufacturing precision
If multiple purification steps are performed to remove reducing agents and capping agents, then the ADC purity is improved, but the manufacturing efficiency and productivity decrease
Solution Approach 1:
The patent merges the conjugation reaction with the purification process by designing a one-pot method where the final purification step removes all intermediates (reducing agents, capping agents, oxidizing agents) and unconjugated cytotoxic agents simultaneously. This eliminates multiple sequential purification operations and significantly improves manufacturing efficiency while maintaining high ADC purity
Solution Approach 2:
The continuous one-pot process allows the conjugation reaction to proceed without interruption by intermediate purifications. The thiol groups remain available for conjugation throughout the process, and the final single purification step removes all unwanted byproducts, thereby maximizing productivity and manufacturing efficiency
3Stability of the object's composition
If selective oxidation is performed to re-form antibody interchain disulfide bonds without oxidizing free thiol groups, then the antibody structure stability is improved, but the process complexity increases due to mild oxidizing agents and purification requirements
Solution Approach 1:
The patent combines the selective oxidation step with the conjugation reaction in a single one-pot process. The mild oxidizing agent is added to the same reaction vessel containing the antibody and cytotoxic agent, allowing simultaneous oxidation of interchain disulfide bonds and conjugation of thiol groups. This eliminates the need for separate oxidation and conjugation steps, reducing process complexity while maintaining antibody structure stability
Solution Approach 2:
The patent uses a capping agent as an intermediary that temporarily protects free thiol groups during the oxidation process. The capping agent prevents oxidation of the thiol groups intended for conjugation while allowing the mild oxidizing agent to re-form interchain disulfide bonds. This intermediary approach simplifies the overall process by eliminating the need for complex selective oxidation conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method increases the purity and yield of ADCs, particularly by maintaining the monomer percentage of the final product, simplifying the manufacturing process and improving efficiency compared to multi-step processes.
Implementation Method 1
reacting a reducing agent with a capped cell-binding agent (cCysCBA) having one or more unpaired cysteine residues capped with a capping agent to form a reduced cell-binding agent, wherein the capping agent is removed to form a free thiol (—SH) group in the reduced cell-binding agent
Implementation Method 2
reacting the reduced cell-binding agent with a selective oxidizing agent to form the CysCBA, wherein the free thiol group in the unpaired cysteine residue is not oxidized
Data Source
AI summary
The present invention provides methods of preparing a cell-binding agent-cytotoxic agent conjugate comprising a cell-binding agent (CysCBA) having one or more unpaired cysteine residues covalently linked to a cytotoxic agent. Also provided are conjugates prepared by the methods described herein and pharmaceutical composition and methods of use thereof.